Literature DB >> 12143043

Normal hepatocytes correct serum bilirubin after repopulation of Gunn rat liver subjected to irradiation/partial resection.

Chandan Guha1, Bhupesh Parashar, Niloy J Deb, Madhur Garg, Giridhar R Gorla, Anupam Singh, Namita Roy-Chowdhury, Bhadrasain Vikram, Jayanta Roy-Chowdhury.   

Abstract

The treatment of inherited metabolic liver diseases by hepatocyte transplantation (HT) would be greatly facilitated if the transplanted normal hepatocytes could be induced to proliferate preferentially over the host liver cells. We hypothesized that preparative hepatic irradiation (HIR) should inhibit host hepatocyte proliferation in response to partial hepatectomy (PH). Normal nonirradiated hepatocytes transplanted in this setting should have a selective growth advantage over the host liver cells and should progressively repopulate the liver. To test this hypothesis, we transplanted 5 million hepatocytes from normal Wistar-Roman High Avoidance (RHA) rats into the livers of congeneic bilirubin-uridine 5'-diphosphoglucuronate glucuronosyltransferase (UGT1A1)-deficient jaundiced Gunn rats by intrasplenic injection after one of the following treatments: (1) 68% PH, (2) HIR (50 Gy), or (3) HIR + PH. In rats receiving either PH or HIR alone before HT, serum bilirubin concentrations declined by 25% to 30% in 28 weeks. In contrast, serum bilirubin levels were normalized completely in rats receiving HIR + PH before HT. Massive repopulation of the Gunn rat liver by the UGT1A1-positive Wistar-RHA hepatocytes was shown by UGT1A1 enzyme assay, immunoblot analysis, and immunohistochemical staining of the recipient liver. High-performance liquid chromatography analysis of the bile collected from Gunn rats 5 months after PH, HIR, and HT showed normalization of the pigment profile, with bilirubin diglucuronide and monoglucuronide as the predominant pigments. In conclusion, a preparative regimen of HIR + PH results in massive repopulation of the liver with functionally normal transplanted hepatocytes, resulting in complete correction of a metabolic deficiency. Noninvasive strategies to replace PH for providing proliferative stimuli to the transplanted cells should make this regimen valuable in augmenting the effects of HT for the treatment of liver diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12143043     DOI: 10.1053/jhep.2002.34516

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

Review 1.  Hepatic stem cells: from inside and outside the liver?

Authors:  M R Alison; P Vig; F Russo; B W Bigger; E Amofah; M Themis; S Forbes
Journal:  Cell Prolif       Date:  2004-02       Impact factor: 6.831

2.  Rescue of lethal hepatic failure by hepatized lymph nodes in mice.

Authors:  Toshitaka Hoppo; Junji Komori; Rohan Manohar; Donna Beer Stolz; Eric Lagasse
Journal:  Gastroenterology       Date:  2010-11-09       Impact factor: 22.682

Review 3.  Hepatocyte Transplantation: Quo Vadis?

Authors:  Mark Barahman; Patrik Asp; Namita Roy-Chowdhury; Milan Kinkhabwala; Jayanta Roy-Chowdhury; Rafi Kabarriti; Chandan Guha
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-29       Impact factor: 7.038

Review 4.  Liver repopulation: a new concept of hepatocyte transplantation.

Authors:  Yujo Kawashita; Chandan Guha; Kosho Yamanouchi; Yuichiro Ito; Yukio Kamohara; Takashi Kanematsu
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

Review 5.  Principles of therapeutic liver repopulation.

Authors:  Markus Grompe
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

Review 6.  Cell delivery: from cell transplantation to organ engineering.

Authors:  Alejandro Soto-Gutierrez; Hiroshi Yagi; Basak E Uygun; Nalu Navarro-Alvarez; Korkut Uygun; Naoya Kobayashi; Yong-Guang Yang; Martin L Yarmush
Journal:  Cell Transplant       Date:  2010-06-03       Impact factor: 4.064

Review 7.  Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease.

Authors:  Ira J Fox; George Q Daley; Steven A Goldman; Johnny Huard; Timothy J Kamp; Massimo Trucco
Journal:  Science       Date:  2014-08-22       Impact factor: 47.728

8.  Effects of Guiyuanfang and autologous transplantation of bone marrow stem cells on rats with liver fibrosis.

Authors:  Li-Mao Wu; Lian-Da Li; Hong Liu; Ke-Yong Ning; Yi-Kui Li
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

Review 9.  Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives.

Authors:  Philippe-A Lysy; Mustapha Najimi; Xavier Stephenne; Annick Bourgois; Francoise Smets; Etienne-M Sokal
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

10.  Bone marrow-derived stromal cell therapy in cirrhosis: clinical evidence, cellular mechanisms, and implications for the treatment of hepatocellular carcinoma.

Authors:  Jeffrey M Vainshtein; Rafi Kabarriti; Keyur J Mehta; Jayanta Roy-Chowdhury; Chandan Guha
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-15       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.